| pembrolizumab based treatment |
| pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide |
| es-BC - HER2 negative - (neo)adjuvant (NA) 1 | |
Comparator:
vs paclitaxel followed by doxorubicin plus cyclophosphamide;
Risk of bias:
low;
some concerns;
high;
NA;